Mouse Monoclonal AMF antibody. Suitable for IHC-P, Flow Cyt, WB, ICC/IF and reacts with Human samples. Cited in 19 publications. Immunogen corresponding to Recombinant Fragment Protein within Human GPI.
View Alternative Names
Glucose-6-phosphate isomerase, GPI, Autocrine motility factor, Neuroleukin, Phosphoglucose isomerase, Phosphohexose isomerase, Sperm antigen 36, AMF, NLK, PGI, PHI, SA-36
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AMF antibody [1B7D7] (AB66340)
ab66340 (1μg/ml) staining AMF in human cerebral cortex using an automated system (DAKO Autostainer Plus). Using this protocol there is strong cytoplasmic staining of neurons and of the neuropil.
Inset panel depicts negative control (no primary antibody).
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer EDTA pH 9.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.</
- Flow Cyt
Unknown
Flow Cytometry - Anti-AMF antibody [1B7D7] (AB66340)
Overlay histogram showing HepG2 cells stained with ab66340 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab66340, 1/100 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H+L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive signal in HepG2 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
- WB
Lab
Western blot - Anti-AMF antibody [1B7D7] (AB66340)
Lanes 1 - 2 : Merged signal (red and green). Green - ab66340 observed at 63 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.
ab66340 was shown to react with AMF in wild-type HEK-293T cells in Western blot with loss of signal observed in GPI knockout cell line ab266834 (GPI knockout cell lysate ab257458). Wild-type HEK-293T and GPI knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab66340 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-AMF antibody [1B7D7] (ab66340) at 1/1000 dilution
Lane 1:
Wild-type HEK-293T cell lysate at 20 µg
Lane 2:
GPI knockout HEK-293T cell lysate at 20 µg
Lane 2:
Western blot - Human GPI (AMF) knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-gpi-amf-knockout-hek-293t-cell-line-ab266834'>ab266834</a>)
Predicted band size: 63 kDa
Observed band size: 63 kDa
false
- WB
Unknown
Western blot - Anti-AMF antibody [1B7D7] (AB66340)
All lanes:
Western blot - Anti-AMF antibody [1B7D7] (ab66340) at 1/2000 dilution
Lane 1:
Cell lysates prepared from HepG2 cells at 100 µg
Lane 2:
Cell lysates prepared from SMMC-7721 cells at 100 µg
Secondary
All lanes:
HRP-conjugated Goat polyclonal to mouse IgG1
Predicted band size: 63 kDa
false
- WB
CiteAb
Western blot - Anti-AMF antibody [1B7D7] (AB66340)
AMF western blot using anti-AMF antibody [1B7D7] ab66340. Publication image and figure legend from Weng, M. L., Chen, W. K., et al., 2020, Nat Commun, PubMed 32313017.
ab66340 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab66340 please see the product overview.
Fasting impairs glycolysis and proliferation of CT26 cells in vitro and in vivo.Fasting inhibited CT26 cell proliferation as measured by a CCK8 assay (from left to right : P = 0.0009; P = 0.0006). b Cell proliferation was also evaluated using EdU immunofluorescence staining. Proliferating cells were labeled with EdU. n = 3; scale bar : 100 μm. c Bioinformatics analysis of differentially expressed genes identified via iTRAQ proteomics. We magnified the genes related to the glycolysis pathway particularly. d The graph shows the relative fold fraction of EdU-positive cells. e Fasting reduced glucose uptake in CT26 cells. f Fasting decreased lactate production via glycolysis in CT26 cells. g Fasting downregulated the expression of rate-limiting glycolytic enzymes in glucose metabolism (GLUT1, HK2, LDHA, PGK1, and GPI) by western blot. h ECAR, an indicator of glycolysis, was reduced in CT26 cell cultured in the fasting mimic medium. i OCR, which reflects mitochondrial respiration, was increased in CT26 cell cultured in the fasting mimic medium. j CT26 cells were injected into BALB/c mice. When the tumors were palpable, the mice were randomly assigned to the control group or the fasting mimic diet (FMD) group. Photograph of dissected tumors (upper : FMD group; lower : control group; n = 5). k Fasting downregulated the transcription of rate-limiting glycolytic enzymes in glucose metabolism (GLUT1, HK2, LDHA, PGK1, and GPI) by qRT-PCR. l The tumor volumes were measured every day after the 9th day. The FMD attenuated tumor growth in mice (n = 5). m, o Tumor weights and tumor volumes on the 25th day (n = 5; P = 0.001; P = 0.0292). n Representative 18F-FDG microPET/CT imaging of tumor-bearing mice (n = 3) (upper : control group; lower : FMD group). The tumors are indicated with arrows. p The ratio of the tumor SUVmax in the control group and the FMD group (n = 3; P = 0.0459). Error bars, mean ± SD, the data are from three independent experiments. Two-sided t tests. *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control group.
false
Reactivity data
Product details
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (19)
Recent publications for all applications. Explore the full list and refine your search
Cell proliferation 56:e13344 PubMed36181462
2022
Applications
Unspecified application
Species
Unspecified reactive species
Acta biochimica et biophysica Sinica 54:625-636 PubMed35593470
2022
Applications
Unspecified application
Species
Unspecified reactive species
Nature cell biology 23:1240-1254 PubMed34887515
2021
Applications
Unspecified application
Species
Unspecified reactive species
Oncology reports 45: PubMed33786631
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 11:789 PubMed32547396
2020
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 11:1869 PubMed32313017
2020
Applications
Unspecified application
Species
Unspecified reactive species
EMBO molecular medicine 11:e10835 PubMed31709724
2019
Applications
Unspecified application
Species
Unspecified reactive species
Cell metabolism 30:903-916.e7 PubMed31523006
2019
Applications
Unspecified application
Species
Unspecified reactive species
Journal of exercise nutrition & biochemistry 23:28-33 PubMed31337203
2019
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in neurology 10:470 PubMed31133972
2019
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com